{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-142816","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2025-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.249289+00:00","generated_at":"2026-05-19T02:40:51.511307+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kura Oncology reports high remission rates with ziftomenib in newly diagnosed AML trial","bullets":["92% CRc (93% NPM1-m, 89% KMT2A-r) among 71 evaluable patients in KOMET-007 trial.","80% complete remission (84% NPM1-m, 74% KMT2A-r); 71% CR-MRD negativity for NPM1-m.","Median time to MRD negativity 4.7 weeks (NPM1-m) and 4.4 weeks (KMT2A-r).","Safety consistent with prior data; no QTc prolongation or additive myelosuppression at 600 mg.","Phase 3 KOMET-017 studies expected to start in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-142816","json":"https://secwatch.observer/filing/0001193125-25-142816.json","markdown":"https://secwatch.observer/filing/0001193125-25-142816.md","text":"https://secwatch.observer/filing/0001193125-25-142816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525142816/0001193125-25-142816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525142816/d939526d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T02:40:51.511307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}